Lilly's Mounjaro wins a CV nod, Teva buys BioXcel's assets, AusperBio raises $120M and Samsung Biologics preps a $2.2B raise.
CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to ...
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in ...
Dimension Capital, an investment firm focused on the convergence of machine learning and life sciences, is raising its third batch of capital and seeking up to $750 million.
Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer.
AstraZeneca and Ionis's Wainua misses in Phase 3 heart trial CARDIO-TTRansform, likely due to overlap with Pfizer's Vyndamax; ...
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
Pharma has much to learn from the surprising boom of telehealth sales of obesity drugs, Novo Nordisk’s CEO Mike Doustdar said at the Endpoints at #JPM26 event on the sidelines of the ...
Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results